Source comparison
BPC-157 vs Cortisone Injections: Mechanism Comparison
Primary Mechanism Upregulates VEGF, FGF, and EGF pathways to stimulate angiogenesis, fibroblast proliferation, and collagen synthesis Binds glucocorticoid receptors to inhibit NF-κB and AP-1, blocking synthesis of IL-1, IL-6, TNF-α, and prostaglandins BPC-157
This comparison does not assign a generated winner or score.
- Primary Mechanism
- Upregulates VEGF, FGF, and EGF pathways to stimulate angiogenesis, fibroblast proliferation, and collagen synthesis
- Binds glucocorticoid receptors to inhibit NF-κB and AP-1, blocking synthesis of IL-1, IL-6, TNF-α, and prostaglandins
- BPC-157 rebuilds tissue; cortisone suppresses immune activity
- Onset of Symptom Relief
- 7–14 days (requires tissue remodeling to reduce pain)
- 24–72 hours (direct suppression of inflammatory mediators)
- Cortisone wins for immediate relief; BPC-157 for structural repair
- Effect on Collagen Production
- Increases Type I and III collagen deposition, improves fiber alignment and cross-linking density
- Inhibits fibroblast activity, reduces collagen synthesis, weakens extracellular matrix integrity
- BPC-157 strengthens tissue long-term; cortisone degrades it
- Impact on Tissue Vascularity
- Promotes neovascularization through VEGF upregulation, increasing oxygen and nutrient delivery to injury site
- No angiogenic effect; prolonged use can reduce capillary density in treated tissue
- BPC-157 improves healing capacity; cortisone does not
- Mechanism of Pain Reduction
- Indirect. Pain decreases as tissue heals and mechanical load tolerance improves
- Direct. Blocks prostaglandin synthesis and cytokine-mediated nociception
- Cortisone masks pain; BPC-157 resolves the structural cause
- Cumulative Risk with Repeated Use
- No documented tissue degradation or cumulative toxicity in animal models at therapeutic doses
- Progressive tendon weakening, increased rupture risk (3.7× higher in Achilles studies), articular cartilage thinning
- BPC-157 safe for extended use; cortisone limited to 3–4 injections/year